AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday.
AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca prostate cancer drug shows promising phase III results
AstraZeneca PLC's (LSE:AZN) Truqap (capivasertib) has shown promising results in a trial for aggressive prostate cancer, improving progression-free survival when combined with standard therapies. The phase III CAPItello-281 trial tested Truqap with abiraterone and androgen deprivation therapy (ADT) against a placebo combination in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, a form of the disease associated with poor outcomes.
Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
